Skip to main content

Table 5 Systematic Review of Recurrence and Long-term Survivals

From: Robotic versus laparoscopic Gastrectomy for gastric cancer: a systematic review and updated meta-analysis

Author Group Stage Chemotherapy Follow-up (mo) Recurrence Survival (%)
Pugliese LG Any TNM0 T3 or any TN+ 53 (3–112) 8a 3y–OS: 85; 5y–OS: 83&
RG 28 (2–44) 4a 3y–OS: 78&
Son T LG Any TNM0 NR 70 3b 5y–DFS: 91.2; 5y–OS: 91.1
RG 3b 5y–DFS: 90.2; 5y–OS: 89.5
Zhou LG Any TNM0 Routinely# 17(3–41) 28 1, 2, 3-OS: 87.3, 77.1, 69.9
3y–OS N:82.6, 3y–OS N+:60.3
RG 5 1, 2, 3-OS: 90.2, 78.1, 67.8
3y–OS N: 84.4, 3y–OS N+: 57.5
Lee LG Any TNM0 NR 75 NR NSD
RG
Han LG cT1-2N0M0 3 cases (4.4%)$ 19.3 0 NSD
RG 3 cases (4.4%)$ 22.7 0
  1. Follow-up time were shown as median (range) or median only
  2. DFS disease-free survival, OS overall survival, y year, N negative nodal metastasis, N + positive nodal metastasis, NR not report, NSD only reported no significant difference between two groups without specific survival rate
  3. asome patients had mixed tumor recurrence, identified recurrence in LG: local (n = 2), peritoneum (n = 2), liver (n = 1), lung (n = 2), bone (n = 1); identified recurrence in RG: peritoneum (n = 1), liver (n = 1), bone (n = 1). &: for overall patients, 5y–OS N: 97%, 5y–OS N+: 52%
  4. bLG, peritoneum (n = 2), lung (n = 1); RG, breast (n = 1), splenic hilum (n = 1), ovary (n = 1). #: 5-fluorouracil + oxaliplatin intravenous chemotherapy. $: because of advanced disease status after surgery